Epidemiology of Pediatric Critical Illness in a Population-Based Birth Cohort in Olmsted County, MN

Sheri S Crow1, Chaitanya Undavalli, David O Warner

  • 11Division of Pediatric Critical Care, Department of Pediatrics and Adolescent Medicine, Department of Health Services Research, Mayo Clinic College of Medicine, Rochester, MN. 2Division of Pediatric Critical Care, Department of Pediatrics and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN. 3Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN. 4Department of Epidemiology and Pediatrics and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN. 5Division of Gastroenterology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN. 6Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN. 7Department of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN. 8Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington School of Medicine, and Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, WA.

Insights

This study reports the first U.S. population-based analysis of pediatric critical illness incidence and presentation in a birth cohort. Findings reveal changing healthcare needs as children develop, with highest intensive care unit (ICU) admission rates in the first year of life.

Area of Science:

  • Pediatric critical care epidemiology
  • Population health research
  • Longitudinal cohort studies

Background:

  • Current pediatric critical illness research often relies on diverse inpatient cohorts.
  • There is a lack of studies examining the full spectrum of critical illness development within a community setting in the U.S.
  • Understanding community-based pediatric critical illness is crucial for public health planning.

Purpose of the Study:

  • To conduct the first epidemiologic report on the incidence and presentation of pediatric critical illness.
  • To analyze data from a U.S. population-based birth cohort.
  • To characterize critical illness across the developmental spectrum in children.

Main Methods:

  • Retrospective cohort study design.
  • Utilized a geographically defined community (Olmsted, MN) with linked medical records across all health systems.
  • Included a birth cohort of 9,441 children born between 2003-2007.

Main Results:

  • Identified 824 intensive care unit (ICU) admissions among 577 children over 61,770 person-years.
  • Incidence of first-time ICU admission was 9.3 per 1,000 person-years, highest in the first year of life.
  • Respiratory problems were common; post-infancy admissions often involved comorbidities, with mortality concentrated in neonates.

Conclusions:

  • This study provides the first characterization of critical illness in a U.S. population-based birth cohort.
  • Results highlight evolving incidence, presentation, and healthcare demands of critical illness as children age.
  • Findings underscore the importance of developmental stage in understanding pediatric critical care needs.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
586
Introduction to Epidemiology01:26

Introduction to Epidemiology

Epidemiology, known as the cornerstone of public health, involves studying the distribution and determinants of health-related events in defined populations and applying these insights to control health issues. This is essential for understanding how diseases spread, identifying populations at greater risk, and implementing measures to control or prevent outbreaks. Epidemiology addresses not only infectious diseases but also non-communicable conditions like cancer and cardiovascular disease,...
2.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304